0KF3 Stock Chart & Stats
$9.61
-$1.04(-10.82%)
At close: 4:00 PM EDT
$9.61
-$1.04(-10.82%)
Day’s Range― - ―
52-Week Range$5.75 - $27.71
Previous CloseN/A
Volume1.00
Average Volume (3M)10.00
Market Cap
$13.70M
Enterprise Value$58.27
Total Cash (Recent Filing)$10.16M
Total Debt (Recent Filing)$286.66K
Price to Earnings (P/E)―
Beta-0.41
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.66
Shares Outstanding1,779,275
10 Day Avg. Volume2
30 Day Avg. Volume10
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$47.50Price Target Upside394.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.31
Revenue Forecast (FY)$12.50M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe completion of the Phase 2 BMT-801 clinical trial is a significant milestone for Palatin as it focuses on the obesity space, which is seen as a key driver of the company's long-term success.
Market OpportunitiesPositive results from the Phase 2 study could validate the potential synergy between bremelanotide and GLP-1 receptor agonists, giving Palatin a foothold in the obesity treatment space.
Bears Say
Funding ChallengesFactors that could impede reaching the price target include failed or inconclusive clinical trials or the inability to secure adequate funding for drug development.
Palatin Technologies News
0KF3 FAQ
What was Palatin Technologies’s price range in the past 12 months?
Palatin Technologies lowest share price was $5.75 and its highest was $27.71 in the past 12 months.
What is Palatin Technologies’s market cap?
Palatin Technologies’s market cap is $13.70M.
When is Palatin Technologies’s upcoming earnings report date?
Palatin Technologies’s upcoming earnings report date is Nov 16, 2026 which is in 102 days.
How were Palatin Technologies’s earnings last quarter?
Palatin Technologies released its earnings results on May 13, 2026. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$1.243 by $0.873.
Is Palatin Technologies overvalued?
According to Wall Street analysts Palatin Technologies’s price is currently Undervalued.
Does Palatin Technologies pay dividends?
Palatin Technologies pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Palatin Technologies dividends here
What is Palatin Technologies’s EPS estimate?
Palatin Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Palatin Technologies have?
Palatin Technologies has 1,779,275 shares outstanding.
What happened to Palatin Technologies’s price movement after its last earnings report?
Palatin Technologies reported an EPS of -$0.37 in its last earnings report, beating expectations of -$1.243. Following the earnings report the stock price went down -15.112%.
Which hedge fund is a major shareholder of Palatin Technologies?
Currently, no hedge funds are holding shares in GB:0KF3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Palatin Technologies
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
0KF3 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced: The call highlighted meaningful near-term commercial validation via upfront collaboration revenue, materially reduced net loss, reduced operating cash burn, strong partnership-driven non-dilutive funding and clear progress across peptide and oral MC4R programs (including IP development). Offsetting these positives are increased operating costs, a limited cash runway to mid-2027 that creates funding risk, a deprioritized earlier oral candidate and timing/competitive risks (notably Rhythm's approved product). Clinical risk around hyperpigmentation and the need for further IND/clinic-readout milestones keep the outlook cautious.View all GB:0KF3 earnings summaries0KF3 Stock 12 Month Forecast
Average Price Target
$47.50
▲(394.28% Upside)